Slingshot members are tracking this event:
Data available 2H from Phase III study of Empliciti in first-line multiple myeloma
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Jun 24, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Multiple Myeloma, Empliciti, Elotuzumab